Stock NAUT NAUTILUS BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Nautilus Biotechnology, Inc.

Equities

NAUT

US63909J1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
2.36 USD -1.67% Intraday chart for Nautilus Biotechnology, Inc. +0.85% -21.07%
Feb. 28 Transcript : Nautilus Biotechnology, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28 Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Number of employees: 167

Managers

Managers TitleAgeSince
Parag Mallick FOU
 Founder 47 15-12-31
Sujal Patel FOU
 Founder 49 15-12-31
Anna Mowry DFI
 Director of Finance/CFO 46 21-06-08
Mary Godwin COO
 Chief Operating Officer 65 19-12-31
Chris Blessington IRO
 Public Communications Contact - 20-12-31
Nick Nelson PRN
 Corporate Officer/Principal 41 21-06-08
Martin Huber PRN
 Corporate Officer/Principal - Oct. 31
Subra Sankar PRN
 Corporate Officer/Principal 64 20-11-30
Matthew Murphy LAW
 General Counsel 59 21-06-08
Gwen Weld HRO
 Human Resources Officer 66 22-04-11

Members of the board

Members of the board TitleAgeSince
Matthew Posard CHM
 Chairman 56 18-12-31
Farzad Nazem BRD
 Director/Board Member 62 21-06-08
Matt McIlwain BRD
 Director/Board Member 59 21-06-08
Sujal Patel FOU
 Founder 49 15-12-31
Michael Altman BRD
 Director/Board Member 42 21-06-08
Melissa Epperly BRD
 Director/Board Member 46 21-06-08
Vijay Pande BRD
 Director/Board Member 53 21-06-08
Parag Mallick FOU
 Founder 47 15-12-31
Karen Akinsanya BRD
 Director/Board Member 56 22-03-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 125,098,080 70,209,342 ( 56.12 %) 0 56.12 %

Shareholders

NameEquities%Valuation
Parag Mallick
16.53 %
20,679,892 16.53 % 61 M $
AH Capital Management LLC
14.11 %
17,653,917 14.11 % 52 M $
Sujal Patel
13.72 %
17,158,999 13.72 % 50 M $
Perceptive Advisors LLC
10.07 %
12,594,211 10.07 % 37 M $
Cercano Management LLC
5.734 %
7,172,985 5.734 % 21 M $
Madrona Venture Group LLC
4.813 %
6,020,770 4.813 % 18 M $
BlackRock Advisors LLC
2.927 %
3,661,489 2.927 % 11 M $
Vanguard Fiduciary Trust Co.
2.262 %
2,829,798 2.262 % 8 M $
Comprehensive Financial Management LLC (California)
1.765 %
2,207,619 1.765 % 6 M $
Bain Capital Life Sciences LP
1.599 %
2,000,000 1.599 % 6 M $

Company contact information

Nautilus Biotechnology, Inc.

2701 Eastlake Avenue East

98102, Seattle

+

http://www.nautilus.bio
address Nautilus Biotechnology, Inc.(NAUT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.36 USD
Average target price
4.25 USD
Spread / Average Target
+80.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NAUTILUS BIOTECHNOLOGY, INC. Stock Nautilus Biotechnology, Inc.
-21.07% 300M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NAUT Stock
  4. Company Nautilus Biotechnology, Inc.